LifeTime and improving European healthcare through cell-based interceptive medicine.

Autor: Rajewsky N; Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany. rajewsky@mdc-berlin.de.; Charité-Universitätsmedizin, Berlin, Germany. rajewsky@mdc-berlin.de.; Berlin Institute of Health (BIH), Berlin, Germany. rajewsky@mdc-berlin.de.; German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany. rajewsky@mdc-berlin.de., Almouzni G; Institut Curie, CNRS, PSL Research University, Sorbonne Université, Nuclear Dynamics Unit, Equipe Labellisée Ligue contre le cancer, Paris, France. genevieve.almouzni@curie.fr., Gorski SA; Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany. stan.gorski@mdc-berlin.de., Aerts S; VIB Center for Brain and Disease Research, Leuven, Belgium.; Department of Human Genetics, KU Leuven, Leuven, Belgium., Amit I; Department of Immunology, Weizmann Institute of Science, Rehovot, Israel., Bertero MG; Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology, Barcelona, Spain., Bock C; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.; Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.; Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, Vienna, Austria., Bredenoord AL; Department of Medical Humanities, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands., Cavalli G; Institute of Human Genetics, UMR 9002, CNRS and University of Montpellier, Montpellier, France., Chiocca S; Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy., Clevers H; Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW), Utrecht, The Netherlands.; University Medical Center Utrecht, Utrecht, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; The Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., De Strooper B; VIB Center for Brain and Disease Research, Leuven, Belgium.; Department of Neurosciences, KU Leuven, Leuven, Belgium.; UK Dementia Research Institute at UCL, University College London, London, UK., Eggert A; Berlin Institute of Health (BIH), Berlin, Germany.; Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany., Ellenberg J; Cell Biology and Biophysics Unit, European Molecular Biology Laboratory, Heidelberg, Germany., Fernández XM; Institut Curie, PSL Research University, Paris, France., Figlerowicz M; Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland.; Institute of Computing Science, Poznan University of Technology, Poznan, Poland., Gasser SM; Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland.; Faculty of Natural Sciences, University of Basel, Basel, Switzerland., Hubner N; Charité-Universitätsmedizin, Berlin, Germany.; Berlin Institute of Health (BIH), Berlin, Germany.; German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany.; Cardiovascular and Metabolic Sciences, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany., Kjems J; Department of Molecular Biology and Genetics (MBG), Aarhus University, Aarhus, Denmark.; Interdisciplinary Nanoscience Centre (iNANO), Aarhus University, Aarhus, Denmark., Knoblich JA; Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna, Austria.; Medical University of Vienna, Vienna, Austria., Krabbe G; Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany., Lichter P; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany., Linnarsson S; Division of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.; Science for Life Laboratory, Stockholm, Sweden., Marine JC; Laboratory for Molecular Cancer Biology, VIB Center for Cancer Biology, KU Leuven, Leuven, Belgium.; Department of Oncology, KU Leuven, Leuven, Belgium., Marioni JC; European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, UK.; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK., Marti-Renom MA; Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology, Barcelona, Spain.; CNAG-CRG, Centre for Genomic Regulation, Barcelona Institute of Science and Technology, Barcelona, Spain.; Universitat Pompeu Fabra, Barcelona, Spain.; ICREA, Barcelona, Spain., Netea MG; Department of Internal Medicine, Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.; Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.; Life and Medical Sciences Institute (LIMES), University of Bonn, Bonn, Germany., Nickel D; Institut Curie, PSL Research University, Paris, France., Nollmann M; Centre de Biochimie Structurale, CNRS UMR 5048, INSERM U1054, Université de Montpellier, Montpellier, France., Novak HR; VIB Technology Watch, Ghent, Belgium., Parkinson H; European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, UK., Piccolo S; Department of Molecular Medicine, University of Padua School of Medicine, Padua, Italy.; IFOM, The FIRC Institute of Molecular Oncology, Padua, Italy., Pinheiro I; Institut Curie, CNRS, PSL Research University, Sorbonne Université, Nuclear Dynamics Unit, Equipe Labellisée Ligue contre le cancer, Paris, France., Pombo A; Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.; Institute for Biology, Humboldt University of Berlin, Berlin, Germany., Popp C; Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany., Reik W; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.; Epigenetics Programme, Babraham Institute, Cambridge, UK.; Centre for Trophoblast Research, University of Cambridge, Cambridge, UK., Roman-Roman S; Department of Translational Research, Institut Curie, PSL Research University, Paris, France., Rosenstiel P; Institute of Clinical Molecular Biology, Kiel University, Kiel, Germany.; University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany., Schultze JL; Life and Medical Sciences Institute (LIMES), University of Bonn, Bonn, Germany.; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.; PRECISE, Platform for Single Cell Genomics and Epigenomics at the German Center for Neurodegenerative Diseases and the University of Bonn, Bonn, Germany., Stegle O; European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, UK.; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.; Division of Computational Genomics and Systems Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Genome Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany., Tanay A; Department of Computer Science and Applied Mathematics, Weizmann Institute of Science, Rehovot, Israel., Testa G; Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.; Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy.; Human Technopole, Milan, Italy., Thanos D; Biomedical Research Foundation, Academy of Athens, Athens, Greece., Theis FJ; Institute of Computational Biology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany.; Department of Mathematics, Technical University of Munich, Munich, Germany., Torres-Padilla ME; Institute of Epigenetics and Stem Cells (IES), Helmholtz Zentrum München - German Research Center for Environmental Health, Munich, Germany.; Faculty of Biology, Ludwig-Maximilians Universität, Munich, Germany., Valencia A; ICREA, Barcelona, Spain.; Barcelona Supercomputing Center (BSC), Barcelona, Spain., Vallot C; Department of Translational Research, Institut Curie, PSL Research University, Paris, France.; CNRS UMR3244, Institut Curie, PSL University, Paris, France., van Oudenaarden A; Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW), Utrecht, The Netherlands.; University Medical Center Utrecht, Utrecht, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Vidal M; Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany., Voet T; Department of Human Genetics, KU Leuven, Leuven, Belgium.; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.
Jazyk: angličtina
Zdroj: Nature [Nature] 2020 Nov; Vol. 587 (7834), pp. 377-386. Date of Electronic Publication: 2020 Sep 07.
DOI: 10.1038/s41586-020-2715-9
Abstrakt: Here we describe the LifeTime Initiative, which aims to track, understand and target human cells during the onset and progression of complex diseases, and to analyse their response to therapy at single-cell resolution. This mission will be implemented through the development, integration and application of single-cell multi-omics and imaging, artificial intelligence and patient-derived experimental disease models during the progression from health to disease. The analysis of large molecular and clinical datasets will identify molecular mechanisms, create predictive computational models of disease progression, and reveal new drug targets and therapies. The timely detection and interception of disease embedded in an ethical and patient-centred vision will be achieved through interactions across academia, hospitals, patient associations, health data management systems and industry. The application of this strategy to key medical challenges in cancer, neurological and neuropsychiatric disorders, and infectious, chronic inflammatory and cardiovascular diseases at the single-cell level will usher in cell-based interceptive medicine in Europe over the next decade.
Databáze: MEDLINE